How do you approach the second-line treatment for a patient with high-risk myeloma relapse early post-autoHCT after Dara-RVD induction?  

Depending on the nature of the relapse, I would salvage with DCEP, or carfilzomib-based triplet (KCyD, KPd) with ciltacel as the next step.

Agree with @Saad Z. Usmani. I typically prefer Dara-KPd or KCd as holding therapy and a bridge to cilta-cel. The subgroup data from CARTITUDE-4 showed that patients with early relapse post-ASCT (defined as <18 months) benefited greatly from cilta-cel (Costa et al., ASCO, 2024) - the 12-month PFS ...